ResearcherSichuan UniversityActive in the last 2 years

Ruiman Geng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9253-9171; OpenAlex author ID A5115595033. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 4

64Cu Radiolabeled PDGFRβ-Targeting Affibody for PET Imaging in Pancreatic Cancer. First author DOI 10.1021/acs.molpharmaceut.4c01368 ↗
TIM-4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL-6 secretion. Co-author DOI 10.1002/cam4.70110 ↗
Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. Co-author DOI 10.1016/j.cbi.2023.110546 ↗
[Inhibition of Copper Transporter-1 by Ammonium Tetrathiocarbolybdate in the Treatment of Pancreatic Cancer]. Co-author DOI 10.12182/20200960101 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Nengwen Ke · 4 shared papers, 2020–2025 · strength 0.75
Ziyao Wang · 2 shared papers, 2023–2024 · strength 0.40
- Paper TIM-4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvir… DOI 10.1002/cam4.70110 ↗
- Paper Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. DOI 10.1016/j.cbi.2023.110546 ↗
Yu Mou · 2 shared papers, 2023–2024 · strength 0.40
- Paper TIM-4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvir… DOI 10.1002/cam4.70110 ↗
- Paper Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. DOI 10.1016/j.cbi.2023.110546 ↗
Huawei Cai · 2 shared papers, 2023–2025 · strength 0.38
- Paper 64Cu Radiolabeled PDGFRβ-Targeting Affibody for PET Imaging in Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.4c01368 ↗
- Paper Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. DOI 10.1016/j.cbi.2023.110546 ↗
Ji Liu · 2 shared papers, 2020–2023 · strength 0.26
- Paper Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. DOI 10.1016/j.cbi.2023.110546 ↗
- Paper [Inhibition of Copper Transporter-1 by Ammonium Tetrathiocarbolybdate in the Treatment of Pancreatic Cancer]. DOI 10.12182/20200960101 ↗
Ruomeng Liu · 1 shared paper, 2025 · strength 0.24
- Paper 64Cu Radiolabeled PDGFRβ-Targeting Affibody for PET Imaging in Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.4c01368 ↗
Li Zhao · 1 shared paper, 2025 · strength 0.24
- Paper 64Cu Radiolabeled PDGFRβ-Targeting Affibody for PET Imaging in Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.4c01368 ↗
Xubao Liu · 1 shared paper, 2023 · strength 0.14
- Paper Copper deprivation enhances the chemosensitivity of pancreatic cancer to rapamycin by mTORC1/2 inhibition. DOI 10.1016/j.cbi.2023.110546 ↗
Ya-Nan Zhao · 1 shared paper, 2020 · strength 0.11
- Paper [Inhibition of Copper Transporter-1 by Ammonium Tetrathiocarbolybdate in the Treatment of Pancreatic Cancer]. DOI 10.12182/20200960101 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.